$7.260
-0.863 (-11.89%)Al cierre
Noticias de EIKN
Eventos de EIKN
Eikon Therapeutics to Present Four Clinical Candidates at 2026 ESMO Congress
Eikon Therapeutics announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology, ESMO, Congress in Madrid, Spain beginning on October 23, 2026. Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer; Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors; Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer; Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies; Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner helicase inhibitor.
Eikon Therapeutics Submits IND Application for EIK1006 to FDA
Eikon Therapeutics announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor antagonist that is structurally unrelated to currently available lutamide-class antagonists.
Eikon Therapeutics Appoints Ching-Pin Chang as Chief Scientific Officer
Eikon Therapeutics (EIKN) announced the appointment of Ching-Pin Chang as executive VP and chief scientific officer. Chang joins Eikon from Bristol Myers (BMY), where he most recently served as VP, head of cardiovascular discovery biology and translational pharmacology.
Eikon Therapeutics Sees Significant Clinical Progress with Seven Abstracts Accepted at ESMO Conference
"The second quarter saw meaningful acceleration of Eikon's most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for presentation at the upcoming ESMO conference in October in Madrid," said Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon Therapeutics. "These new results expand what we reported at the ASCO conference in June and advance our ability to address important unmet needs in cancer therapy. Moreover, our clinical progress reinforces the conclusion that Eikon's unique research platform can reproducibly elucidate novel approaches towards the treatment of grievous illness."
Eikon Therapeutics Sets EIK1001 Dose at 0.60 mg/m2 for TeLuRide-006 Trial
Eikon Therapeutics announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.